Compare Royal Bank of Canada (RY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Sana Biotechnology Inc — how do they compare? Royal Bank of Canada trades at $212.49 (market cap $292.32B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Royal Bank of Canada is far larger — about 258.7× Sana Biotechnology Inc's market cap, and Royal Bank of Canada pays a 2.37% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| RY | SANA | |
|---|---|---|
Market Cap | $292.32B | $1.13B |
Sector | Financials | Health |
52-Week High | $217.87 | $5.92 |
52-Week Low | $134.80 | $2.68 |
Dividend Yield | 2.37% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $212.67, up 0.89% today, with a bullish technical signal and recent quarterly earnings beats. The stock shows strong fundamentals with 2025 revenue of $66.53B and net income of $20.36B, yielding a 31.85% net margin. Analyst consensus is mixed with 43% buy ratings, while recent news highlights insider selling and dividend declarations.
RY presents a solid investment case with robust profitability and dividend appeal, but risks include high valuation multiples and mixed institutional sentiment. Upside is supported by earnings momentum, though macroeconomic and competitive pressures warrant caution for near-term performance.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
